Fig 1.
Schematic diagram of patient flow of Gulf FH study.
*This figure is adapted from the Methodology paper, with only one exception, being the addition of 396 patients thereafter.
Table 1.
Demographic and clinical characteristics of the Gulf FH cohort, stratified by the Dutch Lipid Clinic Network (DLCN) criteria.
Fig 2.
Intensity of statin therapy among the Gulf familial hypercholesterolemia cohort stratified by the Dutch Lipid Clinic Network (DLCN).
**High-intensity statin therapy was defined as those on atorvastatin 40–80 mg and rosuvastatin 20–40 mg while medium-intensity statin therapy was defined as those on atorvastatin 10–20 mg, rosuvastatin 5–10 mg, simvastatin 20–40 mg and pravastatin 40–80 mg. Low intensity statin therapy was defined as those on simvastatin 10 mg or pravastatin 10–20 mg.
Table 2.
Medication status the Gulf FH cohort, stratified by the Dutch Lipid Clinic Network (DLCN) criteria.
Table 3.
Baseline and post-treatment lipid profiles for the Gulf FH cohort, stratified by Dutch Lipid Clinic Network criteria (DLCN).
Fig 3.
LDL and non HDL cholesterol goal attainments in the Gulf FH cohort, stratified by ASCVD risk.
(A) Percentages of subjects that achieved the ESC/EAS-2016 lipid targets. LDL-cholesterol targets were <2.6 mmol/L and <1.8 mmol/L, for the high and very high ASCVD risk groups, respectively; non HDL-cholesterol targets were 3.4 mmol/L and 2.6 mmol/L, for the high and very high ASCVD risk groups, respectively. (B) Percentages of subjects that achieved the ESC/EAS-2019 lipid targets. LDL-cholesterol targets were <1.8 mmol/L and <1.4 mmol/L, for the high and very high ASCVD risk groups, respectively; no HDL-cholesterol targets were <2.6 mmol/L and <2.2 mmol/L, for the high and very high ASCVD risk groups, respectively.